HOME >> BIOLOGY >> NEWS
JCI table of contents -- April 5, 2007

EDITOR'S PICK: Tumors stopped from spreading to new sites

For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cancer, researchers from Vanderbilt University have now generated evidence to suggest that treatment with TGF-beta inhibitors might help such patients.

In the study, which appears online on April 5 in advance of publication in the May print issue of the Journal of Clinical Investigation, Carlos Arteaga and colleagues show that treating mice with mammary tumors with either radiation or the chemotherapeutic drug doxorubicin increased the level of TGF-beta in their blood, the number of cancer cells in their blood, and the development of lung metastases. Treatment with an inhibitor of TGF-beta blocked the increased lung metastases. Furthermore, mice whose tumors did not express the receptor for TGF-beta did not develop increased incidence of lung metastases after treatment with radiation, indicating that TGF-beta affects the cancer cells directly, enhancing their metastatic function. This study has important clinical implications as it suggests that monitoring TGF-beta levels after primary therapy might indicate the patients most at risk of developing tumor metastases and that treatment with TGF-beta inhibitors might be of clinical benefit to these individuals.

TITLE: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

AUTHOR CONTACT:
Carlos L. Arteaga
Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Phone: (615) 936-3524; Fax: (615) 936-1790; E-mail: carlos.arteaga@vanderbilt.edu.

View the PDF of this article at:

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
5-Apr-2007


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents April

(Date:11/21/2014)...  Earlier this year Donald Spector , Chairman ... of the most prolific inventors in the world, got ... Smartphones to third party agencies. Spector envisioned this technology ... the earliest known patents in this area. Now major ... child care, elder care and hospital applications. This technology ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
(Date:11/21/2014)... 2014 Offering a complete line of ... Balance promotion . The Sartorius Entris Balance is the ... accuracy, and easy-to-maintain balance entry level balance. , The ... designed to help customer’s bridge the gap between a ... is very durable. Sartorius is the second biggest balance ...
(Date:11/21/2014)... The report, "Synthetic Biology Market ... kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning ... - Global Forecast to 2018", analyses and ... and challenges. , Browse 99 market data ... pages and in-depth TOC of the global ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 21, 2014 ... is it that makes Albert Einstein so instantly recognizable? ... South African-born physicist, mathematician, astronomer and author Hilton Ratcliffe ... that they have nothing at all to do with ... ( Muse Harbor Publishing , November 21, 2014), Ratcliffe ...
(Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: